Mochida Pharmaceutical Co., Ltd. AI Stock Analysis
Want to see JP:4534 full AI Analyst Report?
Mochida Pharmaceutical Co., Ltd. (4534) AI Stock Analysis
Mochida Pharmaceutical Co., Ltd.
(TSE/TYO:4534)
The overall score of 71 reflects a company with strong fundamentals and an attractive valuation, tempered by cash flow instability. The primary strengths are a rock-solid, low-debt balance sheet and a very low P/E ratio of 11.1, which together suggest a margin of safety. Positive technical momentum supports the near-term outlook. The main risk is the poor cash flow performance in FY2026, which introduces uncertainty about the company's ability to consistently convert profits into cash.
Mochida Pharmaceutical Co., Ltd. (4534) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 113.15B
- Dividend Yield
- 2.48%
- Average Volume (3M)
- 44.59K
- Price to Earnings (P/E)
- 10.9
- Beta (1Y)
- 0.64
- Revenue Growth
- 15.85%
- EPS Growth
- 60.55%
- Country
- Japan
- Employees
- 1,479
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Mochida Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuti...
How the Company Makes Money
Mochida Pharmaceutical primarily makes money by selling pharmaceutical products, with revenue driven mainly by domestic sales of prescription drugs. Its core revenue model is product-based: it develops and/or manufactures medicines and generates inco...
Mochida Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Solid income statement with 9.9% revenue growth and a 39% net income increase, paired with a very strong, low-leverage balance sheet. However, significant cash flow volatility and a negative FY2026 operating cash flow of ¥-7.35B raise concerns about cash generation sustainability, tempering the overall financial health score.
Income Statement
74PositiveBalance Sheet
86Very PositiveCash Flow
45Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 126.33B | 116.95B | 105.16B | 102.89B | 103.26B | 110.18B |
| Gross Profit | 59.50B | 56.26B | 53.79B | 52.07B | 55.12B | 59.55B |
| EBITDA | 15.72B | 13.13B | 11.07B | 8.61B | 11.18B | 17.08B |
| Net Income | 10.75B | 7.90B | 5.68B | 4.55B | 6.65B | 10.57B |
Balance Sheet | ||||||
| Total Assets | 184.91B | 182.72B | 163.56B | 162.30B | 161.04B | 165.93B |
| Cash, Cash Equivalents and Short-Term Investments | 28.57B | 31.06B | 51.15B | 46.79B | 60.51B | 61.91B |
| Total Debt | 10.00B | 10.00B | 342.00M | 369.00M | 178.00M | 0 |
| Total Liabilities | 42.56B | 42.39B | 32.87B | 34.33B | 34.26B | 37.28B |
| Stockholders Equity | 142.35B | 140.33B | 130.69B | 127.97B | 126.78B | 128.65B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -10.04B | 7.19B | -9.78B | 5.13B | 4.47B |
| Operating Cash Flow | 0 | -7.35B | 9.35B | -7.48B | 7.30B | 7.46B |
| Investing Cash Flow | 0 | -16.85B | 17.36B | 74.00M | -2.95B | -2.01B |
| Financing Cash Flow | 0 | 7.03B | -2.87B | -6.39B | -6.88B | -5.96B |
Mochida Pharmaceutical Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4534, the sentiment is Positive. The current price of 3325.00 is above the 20-day moving average (MA) of 3287.25, above the 50-day MA of 3223.91, and above the 200-day MA of 3324.67, indicating a bullish trend. The MACD of 36.68 indicates Negative momentum. The RSI at 54.79 is Neutral, neither overbought nor oversold. The STOCH value of 70.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4534.
Mochida Pharmaceutical Co., Ltd. Peers Comparison
Overall Rating
JP:454773Outperform
JP:453471Outperform
JP:456958Neutral
JP:488756Neutral
JP:452153Neutral
JP:455350Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | JPY 181.97B | 16.55 | 4.95% | 4.60% | 5.87% | -21.16% | |
| 71Outperform | JPY 113.15B | 10.93 | 7.68% | 2.48% | 15.85% | 60.55% | |
| 58Neutral | JPY 58.75B | 160.06 | ― | 4.24% | -6.48% | -95.83% | |
| 56Neutral | JPY 166.15B | 18.57 | ― | 3.36% | 2.43% | ― | |
| 53Neutral | JPY 137.41B | 15.72 | 6.11% | 4.98% | 5.43% | 1167.62% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | JPY 166.84B | 42.26 | 2.10% | 2.36% | 7.06% | -81.10% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4534 | Mochida Pharmaceutical Co., Ltd. | 3325.00 | 103.33 | 3.21% | |
| JP:4521 | Kaken Pharmaceutical Co | 3815.00 | 290.16 | 8.23% | |
| JP:4547 | Kissei Pharmaceutical Co | 4455.00 | 316.01 | 7.63% | |
| JP:4553 | Towa Pharmaceutical Co | 3390.00 | 450.76 | 15.34% | |
| JP:4569 | KYORIN Pharmaceutical Co.,Ltd. | 1108.00 | -278.19 | -20.07% | |
| JP:4887 | SAWAI GROUP HOLDINGS Co., Ltd. | 1667.00 | -178.64 | -9.68% |
Mochida Pharmaceutical Co., Ltd. Corporate Events
Mochida Pharmaceutical Reports Strong First-Half Earnings Growth
Mochida Pharmaceutical, a Japan-listed pharmaceutical company, reported strong first-half performance for the six months ended September 30, 2026. Net sales increased 17.1% year on year to ¥64.4 billion, while operating profit rose 43.0% to ¥7.1 bill...
Mochida Pharmaceutical Repurchases ¥275.4 Million of Shares
Mochida Pharmaceutical repurchased 86,100 common shares for ¥275.4 million during October, using market purchases on the Tokyo Stock Exchange. The transaction forms part of the company’s ongoing share-buyback program and represents continued capital...
Mochida Pharmaceutical Advances TSE Share Buyback Under Board-Approved Program
Mochida Pharmaceutical has disclosed the latest status of its ongoing share buyback program authorized under Japan’s Companies Act. Between September 1 and September 30, 2026, the company repurchased 57,400 of its own common shares via market purchas...
Mochida Pharmaceutical Steps Up Share Buybacks Under 2026 Repurchase Program
Mochida Pharmaceutical Co., Ltd. has continued its share repurchase program, buying 82,000 of its own common shares on the Tokyo Stock Exchange between August 1 and August 31, 2026, at a total cost of ¥264.7 million under a discretionary dealing cont...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
